Lixisenatide vs Orforglipron

Molecule comparison

Last updated 2026-05-28 15:46 UTC

Lixisenatide (brand names Adlyxin and Soliqua) is an injectable GLP-1 drug already approved by the FDA to treat type 2 diabetes. Orforglipron is a new, experimental oral (pill) GLP-1 drug that works similarly but hasn’t been approved for any use yet.

AI summary of the sources below.

	Lixisenatide	Orforglipron
Mechanism	GLP-1 receptor agonist	Oral non-peptide GLP-1 receptor agonist
Status	Approved	Pipeline
Branded products	adlyxin, soliqua	—

Compare full details on the Lixisenatide and Orforglipron pages.